An open-label multicenter, randomized, phase 3 study of S-1 in combination with cisplatin against 5-Fu [fluorouracil] in combination with cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease.
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Fluorouracil
- Indications Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms FLAGS
- Sponsors Taiho Pharmaceutical
- 06 Jun 2017 Results (n=889) of an analysis discovering clinically significant covariate model to identify a patient population with longer survival presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Oct 2012 Results of a non-inferiority analysis presented at the 37th Congress of the European Society for Medical Oncology.
- 15 Mar 2011 S 1 was approved in the EU based in part on the results from this trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History